Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Baxter
Medtronic
McKesson
Merck

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Seribantumab

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Seribantumab?

Seribantumab is an investigational drug.

There have been 5 clinical trials for Seribantumab. The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2017.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, and Ovarian Neoplasms. The leading clinical trial sponsors are Merrimack Pharmaceuticals, Sanofi, and [disabled in preview].

There are two US patents protecting this investigational drug and eight international patents.

Recent Clinical Trials for Seribantumab
TitleSponsorPhase
Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast CancerMerrimack PharmaceuticalsPhase 2
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid TumorsSanofiPhase 1
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid TumorsMerrimack PharmaceuticalsPhase 1

See all Seribantumab clinical trials

Clinical Trial Summary for Seribantumab

Top disease conditions for Seribantumab
Top clinical trial sponsors for Seribantumab

See all Seribantumab clinical trials

US Patents for Seribantumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Seribantumab   Start Trial Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors Merrimack Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Seribantumab   Start Trial Salt of EGFR inhibitor, crystalline form and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Dow
Express Scripts
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.